文献速递产科母胎医学

妊娠期蛋白尿:定义、病理生理学、检测方法与临床意义

Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance.
PubMed 文献 · Am J Obstet Gynecol · 2020-09-01

本文综述妊娠期蛋白尿的定义、病理生理、检测方法及临床意义。24小时尿蛋白定量为参考标准,尿蛋白/肌酐比值可用于排除蛋白尿,尿试纸筛查无临床价值。作者认为子痫前期诊断不必依赖蛋白尿,且不建议对子痫前期患者重复测量蛋白尿。

要点

  • 尿试纸筛查蛋白尿无临床益处,不应用于诊断蛋白尿。
  • 24小时尿蛋白定量为参考标准,尿蛋白/肌酐比值是合理的排除试验。
  • 作者认为对妊娠期高血压患者进行蛋白尿评估可能不必要。

核心结论

  • 影响母儿结局的最重要因素是血压严重程度和终末器官损害,而非尿蛋白排泄量。
  • 作者认为对妊娠20周及以后出现新发血压升高的女性,尿蛋白评估不必要。
  • 作者不推荐对子痫前期女性重复测量蛋白尿,因蛋白尿量似乎与不良母儿结局无关。
  • 作者认为将妊娠期高血压和無严重特征子痫前期分为两种疾病不必要,因两者监测频率和分娩时机管理几乎相同。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 经典定义蛋白尿的截断值为>300 mg/24小时或尿蛋白/肌酐比值至少0.3。
  • 使用该截断值,妊娠期孤立性蛋白尿发生率可达8%,而子痫前期发生于3%至8%的妊娠。
  • 该阈值广泛接受,但其来源基于专家意见和小型研究结果,而非不良妊娠结局证据。
  • 尿蛋白/肌酐比值是合理的排除蛋白尿试验。
  • 尿试纸筛查蛋白尿不提供任何临床益处,不应用于诊断蛋白尿。

关键数值与推荐

  • 蛋白尿定义截断值:>300 mg/24小时或尿蛋白/肌酐比值至少0.3。
  • 妊娠期孤立性蛋白尿发生率可达8%,子痫前期发生率3%至8%。
  • 24小时尿液收集是测量尿蛋白排泄的参考标准。

临床怎么用

  • 作者认为对妊娠20周及以后新发血压升高的女性,尿蛋白评估不必要。
  • 作者不推荐对子痫前期女性重复测量蛋白尿。
  • 在慢性高血压、糖尿病、自身免疫或其他肾脏疾病等情况下,基线蛋白排泄评估至关重要。
  • 对慢性肾脏病女性,子痫前期诊断可能基于蛋白排泄变化。

局限性

  • 当前重叠子痫前期定义存在诊断困境,尚不清楚基线蛋白尿变化是否反映子痫前期等其他系统性疾病。
  • 尚不清楚慢性高血压或糖尿病等慢性疾病女性妊娠期是否经历不同的「正常」蛋白排泄模式。
  • 关于慢性肾脏病女性中血管生成及其他生物标志物作为潜在辅助手段以区分基线慢性肾脏病和慢性高血压恶化与重叠子痫前期的数据有限。
  • 经典蛋白尿阈值来源非基于不良妊娠结局证据,而是基于专家意见和小型研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Qualitative and quantitative measurement of urine protein excretion is one of the most common tests performed during pregnancy. For more than 100 years, proteinuria was necessary for the diagnosis of preeclampsia, but recent guidelines recommend that proteinuria is sufficient but not necessary for the diagnosis. Still, in clinical practice, most patients with gestational hypertension will be diagnosed as having preeclampsia based on the presence of proteinuria. Although the reference standard for measuring urinary protein excretion is a 24-hour urine collection, spot urine protein-to-creatinine ratio is a reasonable "rule-out" test for proteinuria. Urine dipstick screening for proteinuria does not provide any clinical benefit and should not be used to diagnose proteinuria. The classic cutoff cited to define proteinuria during pregnancy is a value of >300 mg/24 hours or a urine protein-to-creatinine ratio of at least 0.3. Using this cutoff, the rate of isolated proteinuria in pregnancy may reach 8%, whereas preeclampsia occurs among 3% to 8% of pregnancies. Although this threshold is widely accepted, its origin is not based on evidence on adverse pregnancy outcomes but rather on expert opinion and results of small studies. After reviewing the available data, the most important factor that influences maternal and neonatal outcome is the severity of blood pressures and presence of end organ damage, rather than the excess protein excretion. Because the management of gestational hypertension and preeclampsia without severe features is almost identical in frequency of surveillance and timing of delivery, the separation into 2 disorders is unnecessary. If the management of women with gestational hypertension with a positive assessment of proteinuria will not change, we believe that urine assessment for proteinuria is unnecessary in women who develop new-onset blood pressure at or after 20 weeks' gestation. Furthermore, we do not recommend repeated measurement of proteinuria for women with preeclampsia, the amount of proteinuria does not seem to be related to poor maternal and neonatal outcomes, and monitoring proteinuria may lead to unindicated preterm deliveries and related neonatal complications. Our current diagnosis of preeclampsia in women with chronic kidney disease may be based on a change in protein excretion, a baseline protein excretion evaluation is critical in certain conditions such as chronic hypertension, diabetes, and autoimmune or other renal disorders. The current definition of superimposed preeclampsia possesses a diagnostic dilemma, and it is unclear whether a change in the baseline proteinuria reflects another systemic disease such as preeclampsia or whether women with chronic disease such as chronic hypertension or diabetes will experience a different "normal" pattern of protein excretion during pregnancy. Finally, limited data are available regarding angiogenic and other biomarkers in women with chronic kidney disease as a potential aid in distinguishing the worsening of baseline chronic kidney disease and chronic hypertension from superimposed preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Fishel Bartal M, Lindheimer MD, Sibai BM, et al. Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. Am J Obstet Gynecol. 2020. PMID: 32882208. doi:10.1016/j.ajog.2020.08.108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。